Profounda Inc.
Orlando, FL
- UEI
- NR1ZD3ETM3N6
- CAGE
- 7K0V7
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 10501 S Orange Ave #124, Orlando, FL 32824, USA
- Website
- profounda.com
- Founded
- 2013
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | -$249,750 |
| FY2025 | $549,450 |
| FY2024 | $249,950 |
| FY2023 | $267,800 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
Profounda Inc., a self-certified small disadvantaged business registered in SAM.gov since February 2016, is a corporate entity specializing in pharmaceutical manufacturing located in Orlando, Florida. The company is primarily focused on producing and distributing specialized medical products, with a particular emphasis on critical pharmaceutical interventions. Profounda Inc. operates as a for-profit organization and has established itself as an exclusive manufacturer and license holder of specific pharmaceutical products, most notably Impavido (miltefosine), which is used to treat rare and complex medical conditions.
The company has an extensive history of federal contract awards, exclusively with the Department of Veterans Affairs (VA) Veterans Health Administration across multiple Veterans Integrated Service Networks (VISNs), including VISN 8, 19, 20, 23, and 16. Profounda Inc. has consistently been awarded firm fixed-price purchase orders for the delivery of Impavido/Miltefosine, a medication used to treat leishmaniasis and other drug-resistant infections. These contracts, ranging from $16,650 to $299,700, are part of a larger $1,127,000 Blanket Purchase Agreement (BPA) that allows for pre-positioning of the medication at VA medical centers. None of the awards have been set aside, and they are typically procured under "Only One Responsible Source" authority, reflecting Profounda's unique position as the exclusive U.S. manufacturer of this critical pharmaceutical product. The contracts demonstrate the company's crucial role in providing emergency medical solutions to the VA healthcare system, ensuring veterans have expedited access to specialized medications.
SBA capabilities narrative
Profounda is a product-oriented, privately backed pharmaceutical company that aims to develop high quality specialty niche pharmaceutical products in both the branded and generic pharmaceutical markets.
Quick answers
Is Profounda Inc. registered in SAM.gov?
Yes. Profounda Inc.'s SAM.gov registration is active through March 3, 2027.
How much has Profounda Inc. received in federal contracts?
Federal contracts obligated $549,450 to Profounda Inc. in fiscal year 2025 and $817,450 in fiscal years 2023 through 2027.
How does Profounda Inc. rank among federal contractors?
Profounda Inc. ranked #89 in NAICS 325412 in FY2025.
What is Profounda Inc.'s most recent federal award?
Profounda Inc.'s most recent federal contract award is Miltefosine (impavido) (36C26025P0684), from Veterans Integrated Service Network 20 (VHA), on May 1, 2025.
On GovTribe
See Profounda Inc.'s full federal record
- Federal contract awards
- IDV awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors